株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国の癌診断市場の見通し:成長機会と戦略

2016-2020 US Cancer Diagnostics Market: Emerging Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Supplier Shares, Country Forecasts, Competitive Strategies, Technologies, Instrumentation

発行 Venture Planning Group 商品コード 237419
出版日 ページ情報 英文 650 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
米国の癌診断市場の見通し:成長機会と戦略 2016-2020 US Cancer Diagnostics Market: Emerging Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Supplier Shares, Country Forecasts, Competitive Strategies, Technologies, Instrumentation
出版日: ページ情報: 英文 650 Pages

当商品の販売は、2016年06月27日を持ちまして終了しました。

概要

当レポートでは、米国における癌診断市場の最新動向と 将来展望について分析し、 検査技術の研究開発の最新動向、市場の基本構造・動向、 今後の市場動向予測、市場拡大のための戦略と課題、 主要企業プロファイルといった情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

世界市場と技術の概要

  • A. 癌の統計および病因論
    • 1. 乳癌
    • 2. 肺癌
    • 3. 大腸/直腸癌
    • 4. 前立腺癌
    • 5. 胃癌
    • 6. 白血病
    • 7. リンパ腫
    • 8. 口腔癌
    • 9. 皮膚癌
    • 10. 子宮癌
    • 11. 卵巣癌
    • 12. 膀胱癌
  • B. 主要な最新癌診断検査
    • 1. イントロダクション
    • 2. 腫瘍マーカー分類
    • 3. ACTH
    • 4.アルファ- フェトプロテイン (AFP)
    • 5. β2ミクログロブリン
    • 6. CA 15-3/27.29
    • 7. CA 19-9
    • 8. CA-125
    • 9. カルシトニン
    • 10. 癌胎児性抗原 (CEA)
    • 11. エストロゲンおよびプロゲステロン受容体
    • 12. フェリチン
    • 13. ガストリン
    • 14. ヒト絨毛性ゴナドトロピン (HCG)
    • 15. インスリン
    • 16. NSE
    • 17. 潜血
    • 18. 子宮頸癌検査/HPV
    • 19. 前立腺酸性フォスファターゼ (PAP)
    • 20. 前立腺特異抗原 (PSA)
    • 21. 扁平上皮癌 抗原 (SCC)
    • 22. T / B リンパ球
    • 23. TdT
    • 24. チログロブリン
    • 25. 組織ポリペプチド抗原 (TPA)
    • 26. 生物学的腫瘍マーカー
    • 27. 癌遺伝子
    • 28. ポリペプチド増殖因子
    • 29. 異所性ホルモン
    • 30. コロニー刺激因子
    • 31. リンフォカイン
    • 32. 免疫組織化学的染色
    • 33. 新たな腫瘍マーカー
  • C. 装置・機器概説および市場ニーズ
    • 1. Abbott AxSYM
    • 2. Abbott Architect c4000
    • 3. Abbott Architect i2000 Series
    • 4. Abbott Architect ci8200 System
    • 5. Beckman Coulter UniCel Series
    • 6. Beckman Coulter Access
    • 7. Binding Site ESP600
    • 8. bioMerieux Mini Vidas
    • 9. Carolina Chemistries BioLis 24i
    • 10. DiaSorin Liaison
    • 11. Horiba ABX Pentra 400
    • 12. Inverness DS2
    • 13. J&J Vitros ECi/ECiQ
    • 14. J&J Vitros 3600
    • 15. J&J Vitros 5600
    • 16. Olympus AU5400
    • 17. Olympus AU3000i
    • 18. Olympus AU2700
    • 19. Roche Modular Analytics
    • 20. Roche Cobas Integra 400
    • 21. Roche Cobas Integra 400 Plus
    • 22. Roche Elecsys
    • 23. Roche Cobas c311
    • 24. Siemens ADVIA Centaur
    • 25. Siemens Dimension
    • 26. Siemens Dimension RxL Max
    • 27. Siemens Dimension Vista 500
    • 28. Siemens Immulite
    • 29. Siemens Stratus
    • 30. Tosoh AIA-Series
    • 31. Vital Diagnostics ATAC 8000
    • 32. Vital Diagnostics Envoy 500
  • D. 最新技術
    • 1. モノクローナル/ポリクローナル抗体
    • 2. 免疫学的測定法
    • 3. 分子診断検査
    • 4. 染色体分析
    • 5. 人工知能
    • 6. フローサイトメトリー
    • 7. 二次元ゲル電気泳動, (2-DGE)
    • 8. バイオセンサー
    • 9. 競合/補完的技術
  • F. 事業環境
    • 1. 市場概観
    • 2. 世界市場の構造
    • 3. 世界市場の規模および成長
  • G. 個人検査

米国市場

  • A. エグゼクティブ・サマリー
  • B. 事業環境
    • 1. 医療費
    • 2. コスト意識
    • 3. 業界再編
    • 4. マネージド・ケア
    • 5. 病院
    • 6. 入院
    • 7. 入院期間
    • 8. 産業多角化
    • 9. 医師の人口統計
    • 10. 人口の高齢化
    • 11. 研究機関に対する規制
  • C. 市場構造
    • 1. 集中型検査
  • D. 市場規模、成長および主要供給業者の消耗品売上、装置機器の設置、市場シェア

主要製品の開発機会

  • A. 試薬キットおよび検査システム/パネル
  • B. 装置・機器類
  • C. コンピュータ、ソフトウェア、オートメーション
  • D. 補助製品

分散型検査製品の設計基準

代替市場浸透戦略

  • A. 内部開発
  • B. 共同開発
  • C. 大学との提携
  • D. 流通戦略
    • 1. マーケティングアプローチ
    • 2. 製品の複雑さ
    • 3. 顧客選好
    • 4. 確立された供給業者
    • 5. 新たな供給業者
    • 6. 主要なタイプの卸売り業者
    • 7. 市場細分化要因

潜在市場の参入障壁およびリスク

  • A. 市場の成熟
  • B. コスト抑制
  • C. 競争
  • D. 技術面での優位性と限界
  • E. 特許保護
  • F. 規制上の制約
  • G. 分散型検査市場の課題

競合プロファイル

  • Abbott
  • AdnaGen
  • Applied Gene Technologies
  • Arca
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Correlogic Systems
  • Dako
  • Decode
  • Diadexus
  • Diagnocure
  • Diasorin
  • Eiken Chemical
  • Enterix
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Gen-Probe
  • Guided Therapeutics
  • Hologic
  • Ipsogen
  • Kreatech
  • Kyowa Medex
  • Life Technologies
  • Mackay Life Sciences
  • Myriad Genetics
  • Nanogen Elitech
  • OncoLab
  • Otho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagnostics & Therapeutics
  • Tosoh
  • Veridex
  • Wako Pure Chemicals
  • Wallac/PE
  • Zila

付録

  • 付録 I:癌診断技術および用途を開発している大学、研究所等
  • 付録 II: 予測為替レート

表一覧

目次
Product Code: VPCA16306

VPGMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the US cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.
 
Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially
significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Cancer Diagnostic Tests—Over 200 current and emerging assays including:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,
Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG,
Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar,
Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone,
Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein,
Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin,
Tissue Polypeptide Antigen, and others.

Market Segmentation Analysis

- Sales and market shares of major suppliers,
by individual cancer diagnostic test.

- Five-year test volume and sales forecasts
for major cancer diagnostic tests by market segment, including:

- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics

- Comprehensive market segmentation analysis, including review
of the market dynamics, structure, size, growth and major suppliers.

- Cancer statistics, etiology and recent developments.

Current and Emerging Products

- Review of over 200 current and emerging cancer diagnostic tests,
including:

- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.

- Analysis of major immunoassay analyzers used for
cancer diagnostic testing, including their operating characteristics,
features and selling prices.

Technology Review

- Assessment of monoclonal antibodies, immunoassays, DNA
probes, biochips/microarrays, chromosome analysis, IT,
artificial intelligence, flow cytometry, biosensors, and other technologies
and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including
CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of over 500 companies, universities
and research centers developing new cancer diagnostic tests
and detection technologies.

Competitive Assessments

- Strategic assessments of major suppliers
and start-up firms developing innovative
technologies and products, including their sales,
product portfolios, marketing tactics, collaborative
arrangements, and new products in R&D.

Contains 620 pages and 103 tables

Table of Contents

Introduction

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

  • 1. Brest Cancer
  • 2. Lung Cancer
  • 3. Colon and Rectum Cancer
  • 4. Prostate Cancer
  • 5. Stomach Cancer
  • 6. Leukemia
  • 7. Lymphoma
  • 8. Oral Cancer
  • 9. Skin Cancer
  • 10. Uterine Cancer
  • 11. Ovarian Cancer
  • 12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

  • 1. Introduction
  • 2. Tumor Marker Classification
  • 3. ACTH
  • 4. Alpha-Fetoprotein (AFP)
  • 5. Beta-2 Microglobulin
  • 6. CA 15-3/27.29
  • 7. CA 19-9
  • 8. CA-125
  • 9. Calcitonin
  • 10. Carcinoembrionic Antigen (CEA)
  • 11. Estrogen and Progesterone Receptors
  • 12. Ferritin
  • 13. Gastrin
  • 14. Human Chorionic Gonadotropin (HCG)
  • 15. Insulin
  • 16. NSE
  • 17. Occult Blood
  • 18. PAP Smear/HPV
  • 19. Prostatic Acid Phosphatase (PAP)
  • 20. Prostate-Specific Antigen (PSA)
  • 21. Squamous Cell Carcinoma Antigen (SCC)
  • 22. T and B Lymphocytes
  • 23. TdT
  • 24. Thyroglobulin
  • 25. Tissue Polypeptide Antigen (TPA)
  • 26. Biochemical Tumor Markers
    • ADA
    • B-Protein
    • PNP
    • 5'-Nucleotidase
  • 27. Oncogenes
    • Abl/abl-bcr
    • AIB1
    • BCL-2
    • BRCA1
    • CD44
    • C-fos
    • C-myb
    • C-myc
    • CYP-17
    • Erb-B
    • HPC1
    • N-myc
    • P40
    • P51
    • P53
    • PIK3CA
    • PTI-1
    • Ras
    • Reg
    • Sis
    • Src
  • 28. Polypeptide Growth Factors
    • Basic Fibroblast Growth Factor
    • Beta-TGF
    • Cachectin (TNT)
    • Calmodulin
    • ECFR
    • Nerve Growth Factor (NGF)
    • Epidermal Growth Factor (EGF)
    • Ornithine Decarboxylase
    • Transferrin
    • Transforming Growth Factor-Alpha
  • 29. Ectopic Hormones
  • 30. Colony Stimulating Factors
  • 31. Lymphokines
    • Alpha-Interferon
    • B Cell Growth Factors
    • B Cell Growth Factor (BCGF)
    • Gamma-Interferon
    • Interleukin-1 (IL-1)
    • Macrophage Activating Factor
  • 32. Immunohistochemical Stains
  • 33. Emerging Tumor Markers
    • N-Acetylglucosamine
    • Actin
    • Alpha-Actin
    • Antineuronal Antibodies
    • 7B2
    • B72.3
    • Bax
    • BCD-F9
    • BLCA-4
    • Blood Group Antigens A,B,H
    • CA 50
    • CA 72-4/TAG-72
    • CA 195
    • CA-242
    • CA-549
    • CAM 26
    • CAR-3
    • Cathepsin-D
    • Chromogranin A and B
    • Cluster 1 Antigen
    • Cluster-5/5A Antigen
    • CTA
    • CU18
    • DR-70
    • DU-PAN-2
    • Endometrial Bleeding Associated Factor
    • Endostatin
    • Epithelial Membrane Antigen
    • Feulgen Hydrolysis
    • Fibronectin
    • FSH
    • (1-$gt;3)-L-fucosyltransferase
    • Gastrin-Releasing Peptide (GRP)
    • GDCFP-15
    • Glucagon
    • Glycoamines
    • H23
    • Her-2
    • Human Carcinoma Antigen
    • HPA
    • HSP27
    • Intermediate Filaments
    • Cytokeratins/CK18/Cyfra 21-1
    • Desmin
    • Gliofibrillary Acid Protein
    • Neurofilaments
    • Vimentin
    • KA 93
    • Kinases
    • KP16D3
    • LAI
    • Leukocyte Common Antigen
    • Lewis Antigens
    • Lysophosphatidic Acid (LPA)
    • Ma 695/Ma 552
    • MABDF3
    • MAG
    • ME1
    • Minactivin
    • MN/CA9
    • MSA
    • Mucin Cancer Antigen (MCA)
    • Multiple Tumor Suppressor 1
    • Myosin
    • NEA-130
    • NMP22
    • OA-519
    • Opiod Peptides
    • P-glycoprotein
    • Pancreatic Oncofetal Antigen (POA)
    • Placental Lactogen
    • PR92
    • Proliferative Index, Ki-67
    • Px
    • RB Inactivation/Deletion
    • Ret
    • SCCL 175
    • Selectin
    • Sialic Acid
    • Sialyl SSEA-1/SLX
    • SN10
    • Somatostatin
    • TA-90
    • TABA
    • Tachykinin
    • TAG 12
    • TPS
    • Troponin
    • Tubulin
    • VCAM
    • VEGF
    • Villen

C. Instrumentation Review And Market Needs

  • 1. Abbott AxSYM
  • 2. Abbott Architect c4000
  • 3. Abbott Architect i2000 Series
  • 4. Abbott Architect ci8200 System
  • 5. Beckman Coulter UniCel Series
  • 6. Beckman Coulter Access
  • 7. Binding Site ESP600
  • 8. bioMerieux Mini Vidas
  • 9. Carolina Chemistries BioLis 24i
  • 10. DiaSorin Liaison
  • 11. Horiba ABX Pentra 400
  • 12. Inverness DS2
  • 13. J&J Vitros ECi/ECiQ
  • 14. J&J Vitros 3600
  • 15. J&J Vitros 5600
  • 16. Olympus AU5400
  • 17. Olympus AU3000i
  • 18. Olympus AU2700
  • 19. Roche Modular Analytics
  • 20. Roche Cobas Integra 400
  • 21. Roche Cobas Integra 400 Plus
  • 22. Roche Elecsys
  • 23. Roche Cobas c311
  • 24. Siemens ADVIA Centaur
  • 25. Siemens Dimension
  • 26. Siemens Dimension RxL Max
  • 27. Siemens Dimension Vista 500
  • 28. Siemens Immulite
  • 29. Siemens Stratus
  • 30. Tosoh AIA-Series
  • 31. Vital Diagnostics ATAC 8000
  • 32. Vital Diagnostics Envoy 500

D. Current and Emerging Technologies

  • 1. Monoclonal and Polyclonal Antibodies
  • 2. Immunoassays
    • a. Technological Principle
    • b. Radioimmunoassay (RIA)
    • c. Enzyme Immunoassays (EIA)
      • Overview
      • ELISA
      • Immunofiltration
      • Particle-Membrane Capture Immunoassay
      • Enzyme Amplification
    • d. Fluorescent Immunoassays
    • e. Luminescence
      • Chemiluminescence
      • Bioluminescence
    • f. Latex Agglutination
    • g. Immunoprecipitation
    • H. Affinity Chromatographu
    • e. Liposome Flow-Injection Immunoassay
  • 3. Molecular Diagnostics
    • a. Technology Overview
    • b. Amplification Methods
      • PCR
      • DAP-PCR
      • Immuno-PCR
      • QC-PCR
      • CAR
      • DNA
      • HPA
      • LCR
      • NASBA
      • QBR
      • SDA
      • 3 SR, and others
  • 4. Chromosome Analysis
    • a. Chronic Myelogenous Leukemia (CML)
    • b. Acute Myeloid Leukemia (AML)
    • c. Acute Lymphoblastic Leukemia (ALL)
    • d. Malignant Lymphomas Lymphoid Malignancies
    • e. Chronic Lymphocytic Leukemia (CLL)
    • f. Solid Cancers
    • g. Chromosomal Translocation and Oncogenes
  • 5. Artificial Intelligence
  • 6. Flow Cytometry
  • 7. Two Dimensional Gel Electrophoresis (2-DGE)
  • 8. Biosensors
  • 9. Competing/Complementing Technologies
    • a. CT
    • b. MRI
    • c. NMR
    • d. PET
    • e. Photonics Spectroscopy

E. Personal Testing

U.S.A.

A. Executive Summary

B. Business Environment

  • 1. Health Care Expenditures
  • 2. Cost Consciousness
  • 3. Industry Consolidation
  • 4. Managed Care
  • 5. Hospitals
  • 6. Admissions
  • 7. Length of Stay
  • 8. Industry Diversification
  • 9. Physician Demographics
  • 10. Population Aging
    • a. Chronic Illness
    • b. Disease Incidence
    • c. Susceptibility to Iatrogenesis
    • d. Multiple Illness Cases
  • 11. Laboratory Regulations

C. Market Structure

  • 1. Centralized Testing
    • a. Hospitals
    • b. Commercial/Private Laboratories
  • 2. POT/Decentralized Testing
    • a. Physician Offices/Group Practices
    • b. Cancer Clinics
    • c. Point-Of-Care Testing
    • d. Other Decentralized Testing Locations

D. Market Size, Growth and Major Suppliers Sales, Instrument Placements and Market Shares Major Product Development Opportunities

  • A. Reagent Kits and Test Systems/Panels
  • B. Instrumentation
  • C. Computers, Software and Automation
  • D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

  • A. Internal Development
  • B. Collaborative Arrangements
  • C. University Contracts
  • D. Distribution Strategies
    • 1. Marketing Approaches
    • 2. Product Complexity
    • 3. Customer Preference
    • 4. Established Suppliers
    • 5. Emerging Suppliers
    • 6. Major Types of Distributors
    • 7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

  • A. Market Maturity
  • B. Cost Containment
  • C. Competition
  • D. Technological Edge and Limitations
  • E. Patent Protection
  • F. Regulatory Constraints
  • G. Decentralized Testing Market Challenges

Competitive Profiles

  • Abbott
  • AdnaGen
  • Applied Gene Technologies
  • Arca
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Correlogic Systems
  • Dako
  • Decode
  • Diadexus
  • Diagnocure
  • Diasorin
  • Eiken Chemical
  • Enterix
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Gen-Probe
  • Guided Therapeutics
  • Hologic
  • Ipsogen
  • Kreatech
  • Kyowa Medex
  • Life Technologies
  • Mackay Life Sciences
  • Myriad Genetics
  • Nanogen Elitech
  • OncoLab
  • Otho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagnostics & Therapeutics
  • Tosoh
  • Veridex
  • Wako Pure Chemicals
  • Wallac/PE
  • Zila

Appendixes

  • Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications
  • Appendix II: Assumed Currency Exchange Rates

List of Tables

  • Tumor Marker Classification
  • Major Companies Developing or Marketing ACTH Tests
  • Major Companies Developing or Marketing AFP Tests
  • Major Companies Developing or Marketing Beta-2 Microglobulin Tests
  • Major Companies Developing or Marketing CA 15-3/27.29 Tests
  • Major Companies Developing or Marketing CA 19-9 Tests
  • Major Companies Developing or Marketing CA 125 Tests
  • Major Companies Developing or Marketing Calcitonin Tests
  • Major Companies Developing or Marketing CEA Tests
  • Major Companies Developing or Marketing Estrogen Receptor Tests
  • Major Companies Developing or Marketing Progesterone Receptor Tests
  • Major Companies Developing or Marketing Ferritin Tests
  • Major Companies Developing or Marketing Gastrin Tests
  • Major Companies Developing or Marketing HCG Tests
  • Major Companies Developing or Marketing Insulin Tests
  • Major Companies Developing or Marketing NSE Tests
  • Major Companies Developing or Marketing Occult Blood Tests
  • Major Companies Developing or Marketing PAP Smear/HPV Tests
  • Major Companies Developing or Marketing PAP Tests
  • Major Companies Developing or Marketing PSA Tests
  • Major Companies Developing or Marketing Lymphocyte Subclassification Tests
  • Biochemical Markers Potential Applications In Cancer Diagnosis
  • Oncogenes Potential Applications In Cancer Diagnosis
  • Major Companies Developing or Marketing Oncogene Tests
  • Growth Factors Potential Applications In Cancer Diagnosis
  • Colony Stimulating Factors Potential Applications in Cancer Diagnosis
  • Lymphokines Potential Applications In Cancer Diagnosis
  • Immunohistochemical Stains Potential Applications in Cancer Diagnosis
  • Executive Summary Table: U.S., Total Tumor Marker Test Volume and Sales Forecast by Market Segment
  • U.S., Estimated New Cancer Cases and Deaths
  • U.S., Estimated Cancer Death Rates Per 100,000 Population
  • U.S., Laboratories Performing Tumor Marker Tests by Market Segment
  • U.S., Hospital Laboratories Performing Tumor Marker Tests by Bed Size
  • U.S., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test Volume
  • U.S., Physician Office Laboratories Performing Tumor Marker Tests by Practice Size
  • U.S., Total Tumor Marker Test Volume Forecast by Market Segment-201
  • U.S., All Market Segments Major Tumor Marker Test Volume Forecast
  • U.S., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
  • U.S., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
  • U.S., Physician Offices/Group Practices Major Tumor Marker Test Volume Forecast
  • U.S., Cancer Clinics Major Tumor Marker Test Volume Forecast by Test
  • U.S., Total Tumor Marker Sales Forecast by Market Segment
  • U.S., All Market Segment Major Tumor Marker Sales Forecast by Test
  • U.S., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
  • U.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
  • U.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by Test
  • U.S., Cancer Clinics Major Tumor Marker Sales Forecast by Test
  • U.S., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Beta-2 Microglobulin Test Volume And Diagnostics Sales Forecast by Market Segment
  • U.S., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CEA Test Volume and Diagnostics Sales by Market Segment
  • U.S., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Colon-specific Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Interferons Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., NSE Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PAP Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PSA Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., TDT Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., TPA Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Total Tumor Marker Sales By Major Supplier
  • U.S., ACTH Testing Market Diagnostics Sales by Major Supplier
  • U.S., AFP Testing Market Diagnostics Sales by Major Supplier
  • U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CEA Testing Market Diagnostics Sales by Major Supplier
  • U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier
  • U.S., HCG Testing Market Diagnostics Sales by Major Supplier
  • U.S., Insulin Testing Market Diagnostics Sales by Major Supplier
  • U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier
  • U.S., PAP Testing Market Diagnostics Sales by Major Supplier
  • U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier
  • U.S., PSA Testing Market Diagnostics Sales by Major Supplier
Back to Top